After an activist investor revolted against the leadership team at Aurinia Pharmaceuticals, the CEO in question is resorting ...

After unveiling a corporate austerity program earlier this year, Germany's Evotec is selling off a piece of its CDMO business ...

Emerging from the rough waters of the CDMO industry with a new chief executive at the helm, AGC Biologics is on a mission to reinvent itself as a manufacturing partner defined by friendliness and e | ...

On Tuesday night, millions of Americans watched as former president Donald J. Trump gathered up enough electoral votes needed ...

AbbVie is reaching for the Sky(rizi) as it spent a staggering $51.5 million on TV drug ads for its immunology blockbuster in October. | AbbVie is reaching for the Sky(rizi) as it spent a staggering ...

Following a disappointing earnings showing from Eli Lilly last week, Novo Nordisk’s latest report on the performance of its ...

As other biopharma giants have divested their generics units to focus on the development and commercialization of innovative ...

What’s an example of a well-executed drug launch? Look no further than Reata’s commercialization of Skyclarys, the first ...

Novavax has inked another settlement for a past COVID-19 vaccine supply deal. | Novavax has inked another settlement for a ...

Election Day is just about here, marking an end to the unpredictable ride that has been the 2024 presidential race following ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...